Press release by the Shihlin District Prosecutors Office, Taiwan

Announcement of the signing of a Non-Binding Letter of Intent for OBI Pharma, Inc., to issue new shares to AbProtix, Inc., in exchange for up to 70% stake in AP Biosciences

Clarification on the news article by Economic Daily News

OBI Pharma granted patent approval for its 2nd Generation Active Immunotherapy Treatment by Taiwan and Australia

Clarification on the news article by Economic Daily News E-Paper

To clarify the media report

Additional charges on Next Digital Ltd., Hong Kong

The company was invited to participate in 17th Annual Asian Technology Conference organized by Credit Suisse

To clarify the media report

OBI Pharma Inc. announces the change of VP, Chief Medical Officer